Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Amyotrophic Lateral Sclerosis (ALS)
NCT07875972Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Sep 2028
01
Overview
Phase 1, open-label trial of orelabrutinib in amyotrophic lateral sclerosis (ALS) (3 cohorts). Primary endpoints: Serious Adverse Event Incidence at Week 28, Adverse Event Incidence and Severity at Week 28 and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07875972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875972.